Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines


This research was designed to provide pharmaceutical sales, marketing, and brand management with data to better understand how US patients will make decisions regarding their purchase and use of biosimilar medications.

  • The general public’s knowledge and perceptions of biologic and biosimilar medications
  • The effect basic biosimilar education has on perceptions and decision-making
  • US population’s current beliefs about generic medicines and how those beliefs differ for “generic” biologics
  • Percentage of US population who know whether their own prescription medications are chemical or biologic
  • Establish your biosimilar commercialization strategy by leveraging this insight into the US population’s knowledge, perceptions, and intentions for use of biologic and biosimilar medicines
  • Design biosimilar patient education campaigns rooted in the understanding of patients’ high-level drivers of choice

1. Executive Summary

2. Medication Decision-making

Explores high-level prescribing activities and reveals patients’ predispositions when making prescription decisions. For example, ISR reveals patients’ likelihood to switch to a generic medication against doctor’s orders, how often they consult a pharmacist regarding drug decisions, and how often they request a generic alternative.

3. Biologic and Biosimilar Prescription Choice Models

ISR analyzes the level of importance patients place on several prescription medication attributes, including: Cost, Doctor recommendation, Manufacturing location, Similarity to the original product, Manufacturer, and Safety record.

To test the impact basic biosimilar education has on patient beliefs and intentions, ISR split the sample into two groups: one that received a brief definition of the difference between biologic and chemical medications and one that did not receive the definition.

4. High-level Medication Perceptions

Reveals patients’ perceptions surrounding “simple” and “complex” medications. For example, ISR explores patients’ perceptions of medication safety and effectiveness, attributes they associate with “complex” medications, and the use and manufacturing of “simple” generic medications.

5. Perceptions of Biologic and Biosimilar Medications 

Quantifies patients’ familiarity with and feelings towards biologic medicines.

6. Pharmaceutical Industry Perceptions

Measures patients’ trust of drug manufacturers by geographic location and reports pharmaceutical company-level brand familiarity.

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at

Additional information


, ,


There are no reviews yet.

Be the first to review “Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines”